3K3A-APC Reduces Neurological Disorders

3K3A-APC Reduces Neurological DisordersScientists discovered a new experimental drug, 3K3A-APC that reduces brain damage, eliminate brain haemorrhaging and improve motor skills in stroke affected mice and rats. According to a new study by Keck Medicine of USC, this drug is also used as therapy for strokes in humans.

This drug can be consumed alone or along with the combination of the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator). Scientists are planning to conduct a survey in which they are testing the efficiency of the drugs in those people suffering with the ischemic stroke.

This survey will begin recruiting the patients in the U. S. in 2014. Berislav V. Zlokovic, MD, PhD, director of the Zilkha Neurogenetic Institute (ZNI) at the Keck School of Medicine of USC, said: "Currently, tPA is the best treatment for stroke caused by a blocked artery, but it must be administered within three hours after stroke onset to be effective".

The new strategy works in the way that 3K3A-APC extends tPA's therapeutic window and counteracts tPA's tendency to encourage bleeding in the brains of those animals suffering with a stroke.

Zlokovic is basically the scientific founder of ZZ Biotech, which is a Houston-based biotechnology company. Zlokovic co-founded with Selim Zilkha, USC benefactor so as to develop biological treatments for stroke and other neurological disorders.